NCT01972152View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Hypoglycemia
Interventions
DRUG

G-Pen(TM) 1 mg

DRUG

Lilly Glucagon(TM) 1 mg

DRUG

G-Pen(TM) 0.5 mg

Trial Locations (1)

78207

Texas Diabetes Institute, University Health System, San Antonio

Sponsors
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Emissary International LLC

INDUSTRY

lead

Xeris Pharmaceuticals

INDUSTRY